Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Eli Lilly reported revenue increased 48% in the most recent quarter, with growth driven by sales of Mounjaro and Zepbound. Mounjaro is indicated for Type 2 diabetes and Zepbound for weight loss management. Both drugs are GLP-1 receptor agonists. The company attributed the increase to demand that exceeded its prior forecasts.

Next story